<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Radiotherapy for locally advanced resectable T3-T4 laryngeal cancer-does laryngeal preservation strategy compromise survival?</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2017-11-28">28 November 2017</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><forename type="first">Hideya</forename><surname>Yamazaki</surname></persName>
							<email>hideya10@hotmail.com</email>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Radiology</orgName>
								<orgName type="department" key="dep2">Graduate School of Medical Science</orgName>
								<orgName type="institution">Kyoto Prefectural University of Medicine</orgName>
								<address>
									<addrLine>465 Kajiicho Kawaramachi Hirokoji, Kamigyo-ku</addrLine>
									<postCode>602-8566</postCode>
									<settlement>Kyoto</settlement>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
							<affiliation key="aff5">
								<orgName type="department">Corresponding author. Department of Radiology</orgName>
								<orgName type="institution">Kyoto Prefectural University of Medicine</orgName>
								<address>
									<addrLine>465 Kajiicho Kawaramachi Hirokoji, Kamigyo-ku</addrLine>
									<postCode>602-8566</postCode>
									<settlement>Kyoto</settlement>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Gen</forename><surname>Suzuki</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Radiology</orgName>
								<orgName type="department" key="dep2">Graduate School of Medical Science</orgName>
								<orgName type="institution">Kyoto Prefectural University of Medicine</orgName>
								<address>
									<addrLine>465 Kajiicho Kawaramachi Hirokoji, Kamigyo-ku</addrLine>
									<postCode>602-8566</postCode>
									<settlement>Kyoto</settlement>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Satoaki</forename><surname>Nakamura</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Radiology</orgName>
								<orgName type="department" key="dep2">Graduate School of Medical Science</orgName>
								<orgName type="institution">Kyoto Prefectural University of Medicine</orgName>
								<address>
									<addrLine>465 Kajiicho Kawaramachi Hirokoji, Kamigyo-ku</addrLine>
									<postCode>602-8566</postCode>
									<settlement>Kyoto</settlement>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Shigeru</forename><surname>Hirano</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Graduate School of Medical Science</orgName>
								<orgName type="institution">Kyoto Prefectural University of Medicine</orgName>
								<address>
									<addrLine>465 Kajiicho Kawaramachi Hirokoji, Kamigyo-ku</addrLine>
									<postCode>602-8566</postCode>
									<settlement>Otorhinolaryngology, Kyoto</settlement>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ken</forename><surname>Yoshida</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Department of Radiology</orgName>
								<orgName type="institution">Osaka Medical College</orgName>
								<address>
									<addrLine>2-7 Daigaku-machi</addrLine>
									<postCode>569-8686</postCode>
									<settlement>Takatsuki-City, Osaka</settlement>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Koji</forename><surname>Konishi</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Department of Radiation Oncology</orgName>
								<orgName type="institution">Osaka International Cancer Institute</orgName>
								<address>
									<postCode>541-8567</postCode>
									<settlement>Osaka</settlement>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Teruki</forename><surname>Teshima</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Department of Radiation Oncology</orgName>
								<orgName type="institution">Osaka International Cancer Institute</orgName>
								<address>
									<postCode>541-8567</postCode>
									<settlement>Osaka</settlement>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Kazuhiko</forename><surname>Ogawa</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Department of Radiation Oncology</orgName>
								<orgName type="institution">Osaka University Graduate School of Medicine</orgName>
								<address>
									<addrLine>Yamadaoka 2-2</addrLine>
									<postCode>565-0871</postCode>
									<settlement>Suita</settlement>
									<region>Osaka</region>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Radiotherapy for locally advanced resectable T3-T4 laryngeal cancer-does laryngeal preservation strategy compromise survival?</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2017-11-28">28 November 2017</date>
						</imprint>
					</monogr>
					<idno type="MD5">D6B3384E5A896A0CB3D418B022E32CF6</idno>
					<idno type="DOI">10.1093/jrr/rrx063</idno>
					<note type="submission">Received 2 July 2017; revised 14 August 2017; editorial decision 1 October 2017</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:31+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>laryngeal cancer</term>
					<term>larynx preservation</term>
					<term>concurrent chemoradiotherapy</term>
					<term>induction chemotherapy</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>With the advancement of chemotherapy, a laryngeal preservation (LP) strategy was explored with the aim of improving maintenance of quality of life.</s><s>Induction chemotherapy (ICT) following radiotherapy (RT) was considered a viable option because of its high initial response rate without hampering of overall survival (OS).</s><s>Subsequently, concurrent chemoradiotherapy (CCRT) using CDDP became the standard of care for LP, showing the best LP ratio.</s><s>For enhancing treatment intensity, ICT with taxan + CDDP + 5-FU (TPF-ICT) followed by RT showed superiority over ICT with CDDP + 5-FU (PF-ICT) followed by RT.</s><s>Given that almost all randomized controlled trials investigating ICT include not only operable (endpoint, LP) but also inoperable (endpoint, OS) cases, physicians are faced with a dilemma regarding application in daily practice.</s><s>In addition, increased treatment intensity causes augmentation of adverse events, which might reduce compliance.</s><s>Thereafter, cetuximab, an effective drug with fewer adverse effects [bioradiotherapy (BRT)], emerged as another option.</s><s>However, little evidence has confirmed its superiority over RT (or CCRT) in laryngeal cancer subpopulations.</s><s>In spite of these developments, the OS of patients with laryngeal cancer has not improved for several decades.</s><s>In fact, several studies indicated a decrease in OS during the 1990s, probably due to overuse of CCRT.</s><s>Fortunately, the latter was not the case in most institutions.</s><s>Currently, no other treatment has better OS than surgery.</s><s>The eligibility criteria for LP and/or surgery largely depend upon the available expertise and experience, which differ from one institution to another.</s><s>Therefore, a multidisciplinary team is required for the treatment of LP.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>INTRODUCTION</head><p><s>Squamous cell carcinoma (SCC) of the head and neck is the sixth most common type of cancer worldwide, with over 650 000 new diagnoses every year <ref type="bibr" target="#b0">[1]</ref>, while laryngeal cancer accounts for ~200 000 deaths annually <ref type="bibr" target="#b1">[2]</ref>.</s><s>Although laryngeal cancer represents only 2-5% of all malignancies, it is particularly important to (CR) rates of 35-55% <ref type="bibr" target="#b2">[3,</ref><ref type="bibr" target="#b3">4]</ref>.</s><s>Thereafter, a combination of these chemotherapeutic agents with radiotherapy (RT) had been explored as a substitute for surgical intervention for laryngeal preservation (LP) <ref type="bibr" target="#b4">[5,</ref><ref type="bibr" target="#b5">6]</ref>.</s><s>The Veterans Administration Laryngeal Cancer Study Group trial (henceforth, the VA study) confirmed the compatibility of ICT → RT and surgery → RT, supporting and emphasizing the merits of this regimen in maintaining quality of life by avoiding laryngectomy <ref type="bibr" target="#b6">[7]</ref>.</s><s>Concurrent CDDP + RT (concurrent chemoradiotherapy [CCRT] = with CDDP, unless otherwise stated) has also been validated for usefulness by the RTOG 99-11 trial and became and still is a standard of care for LP <ref type="bibr" target="#b7">[8,</ref><ref type="bibr" target="#b8">9]</ref>.</s><s>Subsequent ICT studies carried out mainly in mixed populations (unresectable and resectable diseases) established the superiority of docetaxel, CDDP and 5-FU (TPF-ICT) over PF-ICT <ref type="bibr" target="#b9">[10,</ref><ref type="bibr" target="#b10">11]</ref>.</s><s>Unexpectedly, after the establishment of CCRT's role in LP, several studies noted a decline in the survival rates for laryngeal cancer patients during the late 1990s <ref type="bibr" target="#b11">[12,</ref><ref type="bibr" target="#b12">13]</ref>, with a trend in increasing CCRT dissemination (and a simultaneous decrease in surgeries).</s><s>The studies' investigators hypothesized that overuse of CCRT may compromise survival, which brought about wide controversy.</s><s>In addition, bioradiotherapy (BRT) emerged as an alternative treatment for cases where CDDP was unavailable, despite insufficient evidence for its effectiveness for laryngeal cancer subpopulations <ref type="bibr" target="#b13">[14]</ref>.</s><s>Consequently, we encountered difficulty in selecting from the various treatment options for locally advanced laryngeal cancer, which ranged from laryngectomy (surgery [S], with or without following RT) to LP treatment (upfront CCRT or ICT → RT/CCRT/BRT).</s><s>In addition, considering LP as the primary endpoint carries the risk of obscuring the differences between disease control, LP rates, and quality of life.</s><s>Therefore, the endpoint should be a combination of survival and laryngoesophageal function.</s><s>Patients with advanced laryngeal cancer who present with poor functional status, manifested by severe airway compromise requiring a tracheostomy or enteric feeding, are poor candidates for LP.</s><s>As a result, it is difficult to apply the outcomes of randomized controlled trials (RCTs) directly into daily clinical practice.</s><s>Given the confounding nature of these considerations (indication, patient will, need for a multidisciplinary team, etc.), especially for resectable cases, we have produced this narrative review of the role of RT in locally advanced resectable laryngeal cancer.</s><s>This review summarizes retrospective and prospective clinical data in resectable T3-4 laryngeal cancer, investigating the larynx preservation strategy by radiotherapy, with a focus on the LP.</s><s>To identify suitable publications, the search strategy was as follows.</s><s>The Medline database was searched by entering all possible combinations of one of the following key words: 'radiation/radiotherapy', 'laryngeal cancer', 'locally advanced', 'T3 or T4', 'larynx preservation'.</s><s>Thus, the aim of this study was to raise and investigate two questions for resectable T3-4 laryngeal cancer: (i) Is an LP strategy feasible?</s><s>(ii) Which treatment protocol is best?'</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>RETROSPECTIVE DATA ABOUT T3-T4 LARYNGEAL CANCER</head><p><s>T3 tumors are good candidates for LP after early RT, depending on patient preference (Table <ref type="table" target="#tab_1">1</ref>).</s><s>In contrast, T4 tumors, especially large instances, have been treated mainly by surgery.</s><s>Intensive research has been undertaken in order to improve patient outcomes for advanced disease.</s><s>For instance, non-standard alternated fractionation (acceleration of hyperfractionation, etc.) has been extensively trialled in several institutions (Table <ref type="table" target="#tab_1">1</ref>) <ref type="bibr" target="#b14">[15]</ref>.</s><s>Mendenhall et al.</s></p><p><s>reported that the probability of cure was ~65-80% for select lowvolume (≤3.5 cm 3 ) T3 to T4 glottic SCCs after RT <ref type="bibr" target="#b15">[16]</ref>.</s><s>Shiao et al. reported that patients with a tumor volume of ≥21 cm 3 had significantly inferior 5-year overall survival (OS) compared with those with a tumor volume of &lt;21 cm 3 (42% vs 64%; P = 0.003) <ref type="bibr" target="#b16">[17]</ref>.</s><s>Moreover, Mendenhall et al. recommended that highervolume tumors, particularly those that compromised the airway, should be treated with laryngectomy and postoperative RT, because RT outcomes for T4 laryngeal cancer were generally poor and occasionally resulted in a non-functioning larynx <ref type="bibr" target="#b15">[16,</ref><ref type="bibr" target="#b17">18]</ref>.</s><s>Fuller et al. eschewed LP in patients with both T3 and T4 laryngeal cancer who, after a pretreatment barium swallow test and/or video stroboscope evaluation, had poor baseline airway function, evidenced by demonstrable aspiration to a degree wherein airway protection after therapy was not possible <ref type="bibr" target="#b24">[25]</ref>.</s><s>For this reason, careful multidisciplinary evaluation, including direct pretherapy assessment by medical oncologists, head and neck surgeons, radiation oncologists, diagnostic radiologists, pathologists, and experienced speech pathology personnel, is imperative.</s><s>Tracheostomy or feeding-tube dependency is also regarded as an indicator for poor future laryngoesophageal function; however, several experienced institutions have achieved good results for patients exhibiting these characteristics, even for those with T4 tumors <ref type="bibr" target="#b18">[19,</ref><ref type="bibr" target="#b19">20]</ref>.</s></p><p><s>Notably, 'unresectable' does not always mean 'inoperable.'</s><s>The definition of 'inoperable' varies among institutions.</s><s>Usually, the term unresectable has been used for infiltrative tumors that involve the cervical vertebrae, brachial plexus, deep muscles of the neck, and carotid artery.</s><s>Poor prognostic factors have been considered to include direct invasion of the skin, mediastinal structures, or prevertebral fascia.</s><s>Furthermore, patients who have refused surgery have also occasionally been included in the unresectable group.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>PROSPECTIVE STUDIES OF T3-T4 LARYNGEAL CANCER</head><p><s>From surgery to LP treatment</s></p><p><s>The advent of systemic therapy [chemotherapy (CDDP, 5-FU, and Paclitaxel)] in the 1980s brought with it the potential for improving survival without performing functionally debilitating surgery <ref type="bibr" target="#b4">[5,</ref><ref type="bibr" target="#b5">6]</ref>.</s></p><p><s>During the succeeding decades, two general substitution approaches evolved for the treatment of locally advanced cancers that require total laryngectomy (Table <ref type="table" target="#tab_2">2</ref>): ICT → RT (or CCRT), which is favored in Europe, and concomitant CDDP and standard fractionation RT (CCRT), which is preferred in North America.</s></p><p><s>Comparison with surgery (control arm: S ± RT)  <ref type="bibr" target="#b7">[8,</ref><ref type="bibr" target="#b29">30]</ref>.</s><s>The primary endpoint was laryngectomy-free survival (with laryngectomy or death treated as events in this trial).</s><s>After 2 years, the CCRT arm exhibited a higher LP ratio (88%) than the ICT → RT (75%, P = 0.005) or RT (70%, P &lt; 0.001) arm.</s><s>Locoregional control rates were also significantly better with CCRT (78%) compared with ICT → RT alone (61%) and RT (56%).</s><s>Moreover, 5-year OS rates for RT alone, CCRT, and ICT were 54%, 55% and 58%, respectively, all of which are relatively similar.</s><s>However, the survival curves diverged after 4.5 years, with 10-year OS rates of 32%, 28% and 39% for RT only, CCRT, and ICT → RT, respectively, thus presenting ICT as the superior treatment.</s><s>It is possible that unrecognized or under-reported late toxicities could have contributed to some of the non-cancer-related deaths that emerged with the long follow-up period.</s><s><ref type="bibr" target="#b30">[31]</ref>.</s><s>Furthermore, 82% and 98% of the patients in the RT and CCRT arms had been rendered disease free (P = 0.02), respectively.</s><s>For RT vs CCRT, the 5-year OS rates, OS rates with primary site preservation, and local control rates without surgical resection were 48% vs 50% (P = 0.55), 34% vs 42% (P = 0.004) and 45% vs 77% (P &lt; 0.001), respectively.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Induction chemotherapy Comparison with PF-ICT (control arm: PF-ICT → RT or CCRT)</head><p><s>To enhance treatment intensity, regimens containing taxan (docetaxel or paclitaxel) were intensely explored.</s><s>Generally, TPF-ICT showed superior outcomes compared with PF for several RCTs.</s><s>However, a number of these RCTs were criticized for their use of non-standard approaches, leaving the regimen suitable for replacing the present standard treatment.</s><s>Progression-free survival (PFS) was also significantly better in patients treated with TPF-ICT than with PF-ICT (median 38.1 months vs 13.2 months).</s><s>No significant difference was found for dependence on gastric feeding tubes (3% vs 11%) or tracheostomies (7% vs 11%) between the treatment groups.</s><s>They also made a subpopulation analysis limited to laryngeal (54% of entire population) and hypopharyngeal cancers (74% operable: 90 PF-ICT and 76 TPF-ICT patients) <ref type="bibr" target="#b35">[36]</ref>.</s><s>OS rates for laryngeal cancer in the PF-ICT and TPF-ICT groups were 45% and 65% (P &lt; 0.05), respectively.</s><s>In the operable group, the 3-year laryngectomy-free survival rates for TPF-ICT and PF-ICT were 52% and 32% (P = 0.03), respectively.</s><s>The main point of criticism was the use of a nonstandard CCRT regimen (carboplatin).</s><s>showed equivalent outcomes for TPF-ICT (×2) (docetaxel 75 mg/m 2 Day 1, CDDP 75 mg/m 2 Day 1, 5-FU 750 mg/m 2 Days 1-5) → CCRT (docetaxel, 5-FU, and hydroxyurea + RT 1.5 Gy twice per day every other week) and upfront CCRT in N2 or N3 disease <ref type="bibr" target="#b37">[38]</ref>.</s><s>Grade 3-4 toxicities included febrile neutropenia (11%) and mucositis (9%) during ICT and mucositis (49%), dermatitis (21%), and leukopenia (18%) during CCRT (both arms combined).</s><s>Serious adverse events were more common in the ICT arm than in the CCRT arm (47% vs 28%; P = 0.002).</s><s>There were no statistically significant differences in OS or RFS.</s><s>Paccagnella et al. suggested the superiority of TPF-ICT (×3) (docetaxel 75 mg/m 2 , CDDP 80 mg/m 2 Day 1, 5-FU 800 mg/m 2 96 h every 3 weeks, n = 51) → CCRT over CCRT alone (CDDP 20 mg/m 2 Days 1-4, 5-FU 800 mg/m 2 Week 1 and Week 6, 66-70 Gy, n = 50) in terms of initial response <ref type="bibr" target="#b38">[39]</ref>.</s><s>TPF-ICT → CCRT achieved 50% of the primary endpoint (CR at 6-8 weeks after CCRT), whereas CCRT alone achieved 21% (P = 0.004).</s><s>The CCRT and TPF-ICT → CCRT groups had an MST of 33.3 and 39.6 months (P = 0.268), respectively.</s><s>This study used a nonstandard chemotherapeutic drug dose for CCRT (Table <ref type="table" target="#tab_6">3</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Other trials</head><p><s>The CONDOR trial</s></p><p><s>The CONDOR trial examined the role of alternated RT after four courses of TPF-ICT → CCRT × 4 (CDDP 100 mg/m 2 = cis100 + RT 70 Gy/35 fr including intensity-modulated RT) or CDDP 40 mg/m 2 weekly with accelerated RT (=cis40 + accelerated RT; ART: 6 fr/wk = 70 Gy/6 wks) <ref type="bibr" target="#b39">[40]</ref>.</s><s>Unfortunately, the data safety monitoring board advised premature termination of the study, because only 22% and 41% (32% in total) of the patients treated with cis100 + RT (n = 27) and cis40 + ART (n = 29) could receive the planned CDDP dose during CCRT, respectively.</s><s>This trial revealed the difficulty of performing CCRT after TPF-ICT.</s><s>In addition, Hitt et al. showed that ICT had significantly better PFS than CCRT alone in the per protocol population <ref type="bibr" target="#b40">[41]</ref>.</s><s>These data suggested that ICT could be beneficial for patients who can complete the treatment protocol.</s><s>On the other hand, ICT might only delay CCRT in those who are unable to complete the treatment protocol, without any benefit except for additional therapeutic toxicity.</s><s>Therefore, patient selection is an important issue for future trials <ref type="bibr" target="#b41">[42,</ref><ref type="bibr" target="#b42">43]</ref>.</s><s>Michigan University <ref type="bibr" target="#b42">[43]</ref> and Popovtzer et al. proposed chemotherapy selection during the first cycle of TPF-ICT <ref type="bibr" target="#b41">[42]</ref>, with responses being determined by examination and positron emission tomography (PET)-CT.</s><s>In those studies, responders (&gt;50% tumor reduction) underwent chemoradiation, whereas non-responders underwent laryngectomy.</s><s>A total of 83% of the patients responded to the treatment, while 17% had stable or progressive disease.</s><s>After 2 years, the median OS rate, LP rate and disease-specific survival rate were 80%, 83% and 86%, respectively.</s><s>Response to a single TPF cycle was associated with 2-year OS (92% vs 50%; P = 0.02).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Meta-analysis of chemotherapy in head and neck cancer</head><p><s>The pivotal Meta-Analysis of Chemotherapy in Head and Neck Cancer (MACH-NC) study was first reported in 2002 and updated in 2009 (87 trials and 16 485 patients) <ref type="bibr" target="#b43">[44,</ref><ref type="bibr" target="#b44">45]</ref>.</s><s>These studies concluded that CCRT proved to be considerably more successful than alternative treatments.</s><s>Adding ICT (PF-ICT) to locoregional treatment was associated with a slight improvement in OS and distant failure.</s><s>The HR of death was 0.88 (P &lt; 0.0001), with an absolute chemotherapy benefit of 4.5% at 5 years.</s><s>CCRT showed a more pronounced benefit compared with ICT.</s><s>The HR for CCRT was 0.81 (P &lt; 0.0001), with an absolute benefit of 6.5% at 5 years.</s><s>A decrease in the effects of chemotherapy was observed with age (P = 0.003, test for trend).</s><s>In addition, despite current intensive efforts, no form of acceleration can potentially fully compensate for the lack of concurrent chemotherapy <ref type="bibr" target="#b14">[15,</ref><ref type="bibr" target="#b45">46]</ref>.</s></p><p><s>Several meta-analyses have been performed to answer subsequent questions <ref type="bibr" target="#b46">[47]</ref><ref type="bibr" target="#b47">[48]</ref><ref type="bibr" target="#b48">[49]</ref>.</s><s>Comparing PF-ICT and TPF-ICT in 1772 patients, Blanchard et al. <ref type="bibr" target="#b8">[9]</ref> showed that TPF-ICT had an absolute benefit of 7.4% after 5 years and was associated with a significant reduction in progression, locoregional failure, and distant failure when compared with PF-ICT <ref type="bibr" target="#b8">[9]</ref>.</s><s>However, only 49% of patients treated with taxanes were able to complete sequential CCRT as planned.</s><s>Kim et al. also concluded that ICT using TPF-ICT followed by CCRT did not improve OS <ref type="bibr" target="#b10">[11]</ref>, although PFS and response rates were significantly improved.</s><s>Furthermore, Gyawali et al. concluded that concurrent CCRT should be preferred over ICT at present <ref type="bibr" target="#b9">[10]</ref> (Table <ref type="table" target="#tab_7">4</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BRT (cetuximab)-is BRT safer than CCRT?</head><p><s>The Bonner trial</s></p><p><s>Bonner et al. introduced BRT (cetuximab + RT) for the treatment of advanced head and neck cancers <ref type="bibr" target="#b14">[15,</ref><ref type="bibr" target="#b50">51]</ref>.</s><s>After comparing RT and BRT (an initial dose of 400 mg cetuximab, a monoclonal antibody against the epidermal growth factor receptor, followed by 250 mg/m 2 weekly for the duration of RT), response rates of 64% and 74% were found in the RT and BRT arms (P = 0.02), respectively.</s><s>The median durations of locoregional control were 24.4 and 14.9 months for BRT and RT (HR 0.68; P = 0.005), respectively.</s><s>BRT significantly prolonged PFS (HR 0.70; P = 0.006) and OS.</s><s>Except for acneiform rash and infusion reactions, the incidence of Grade 3 or greater toxic effects, including mucositis, did not differ significantly between the two groups.</s><s>However, subpopulation analysis showed that BRT was not superior to RT alone for laryngeal cancer <ref type="bibr" target="#b52">[53]</ref>.</s><s>Although BRT has been extensively explored since this trial, it has thus far failed to establish its superiority in laryngeal cancer treatment.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Radiotherapy With Cisplatin Vs Radiotherapy With Cetuximab After Induction Chemotherapy for Larynx Preservation (TREMPLIN) (GORTEC + GETTEC)</head><p><s>The TREMPLIN study compared CCRT and BRT for LP <ref type="bibr" target="#b49">[50]</ref> in 153 operable patients (laryngeal or hypopharyngeal cancer, T2-T3 and N0-N3) after TPF-ICT.</s><s>The primary endpoint was LP 3 months after treatment, with an expected rate of 80%.</s><s>Secondary endpoints were laryngeal function preservation (LFP) and OS at 18 months.</s><s>Among the 156 patients who received TPF-ICT, 126 (86%) achieved PR ≤ and 23 patients &lt;PR (non-responders received S <ref type="bibr" target="#b15">[16]</ref> or RT <ref type="bibr" target="#b6">[7]</ref>).</s><s>Subsequently, 116 patients (76% of those included in the TPF-ICT group) were categorized into CCRT (60) (70 Gy/35 fr) or BRT (56) (70 Gy/35 fr).</s><s>No significant difference between BRT and CCRT was observed with regard to LP at 3 months (95% and 93%), LFP (87% and 82%) or OS at 18 months (92% and 89%).</s><s>Unfortunately, considering the 24% of patients who dropped out, the trial did not reach the expected 80% LP 3 months after treatment.</s><s>Though BRT was shown to be as toxic as CCRT, causing the same rate of Grade 3 to 4 acute mucositis, it had worse in-field skin toxicity.</s><s>More local failures (8.3% vs 14.3% at 18 months) among patients treated with cetuximab raised the possibility that BRT may be inferior to CCRT for achieving local control in laryngeal cancer.</s><s>This is the only RCT providing evidence for the similarity in the outcomes of TPF-ICT → BRT and TPF-ICT → CCRT.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>RTOG0522</head><p><s>Ang et al. made a comparison between CCRT and CCRT + cetuximab (BCCRT) <ref type="bibr" target="#b51">[52]</ref>.</s><s>RT (72 Gy/42 fr/6 weeks: twice a day for 6 days) was delivered as scheduled.</s><s>When IMRT was used, the protocol was changed to twice a day once a week for 5 weeks (70 Gy/35 fr/6 weeks).</s><s>Compared with CCRT, BCCRT had more frequent RT interruptions (26.9% vs 15.1%), similar CDDP delivery (mean, 185.7 mg/m 2 vs 191.1 mg/m 2 ) and more Grade 3-4 radiation mucositis (43.2% vs 33.3%), rash, fatigue, anorexia, and hypokalemia toxicities but less late toxicity.</s><s>Similar outcome was obtained; 3-year PFS (61.2% vs 58.9%), 3-year OS (72.9% vs 75.8%), locoregional failure (19.9% vs 25.9%) and distant metastasis (13.0%</s><s>vs 9.7%; P = 0.08).</s><s>Patients with p16-positive oropharyngeal carcinoma (OPC) showed better PFS (72.8% vs 49.2%; P &lt; 0.001) and OS (85.6% vs 60.1%, P &lt; 0.001) than those with p16-negative OPC.</s><s>Subpopulation analysis showed an inclination similar to that shown in the Bonner trial, wherein CCRT seemed to be superior to BCCRT in patients with laryngeal cancer.</s><s>Magrini et al. made a direct comparison (Phase II trial) between CCRT (70 Gy/35 fr + CDDP 40 mg/m 2 /wk) and BRT, concluding that BRT lowered compliance, increased acute toxicity rates, and had similar efficacy as compared with CCRT <ref type="bibr" target="#b52">[53]</ref>.</s><s>The endpoints included compliance, toxicity and efficacy.</s><s>The study was discontinued early because of slow accrual after the enrollment of 70 patients.</s><s>RT discontinuation for more than 10 days occurred in 13% and 0% of the patients receiving BRT and CDDP (P = 0.05), respectively.</s><s>Hematologic, renal and GI toxicities were more frequent in the CDDP arm, whereas cutaneous toxicity and the need for nutritional support were more frequent in the BRT arm.</s><s>Serious adverse events were higher in the BRT arm than in the CDDP arm (19% vs 3%, P = 0.044; including 4 vs 1 toxic deaths).</s><s>Although efficacies were similar, BRT toxicity was higher than expected.</s></p><p><s>A German LP trial <ref type="bibr" target="#b53">[54]</ref> utilized a protocol with three cycles of TPF-ICT (dose according to the TAX 323 trial) → CCRT (concomitant boost RT) with or without cetuximab for 16 weeks (starting with ICT and continuing with RT) in 180 patients.</s><s>In case of non-response after the first cycle, salvage laryngectomy was performed.</s><s>The investigators omitted 5-FU following four therapyrelated deaths at the beginning of the trial.</s><s>The addition of cetuximab to TPF-ICT seems to have profound effects on toxicity.</s><s>Studies attempting to add cetuximab to TPF-ICT showed excessive toxicity.</s><s>Therefore, current research has explored the possibility of omitting 5-FU and replacing it with cetuximab.</s></p><p><s>Petrelli et al. performed a meta-analysis including 15 trials (1808 patients) to assess the role of BRT <ref type="bibr" target="#b54">[55]</ref>.</s><s>Overall, CCRT significantly improved 2-year OS (response rate = 0.66; P = 0.02), 2-year PFS (response rate = 0.68; P = 0.002), and 2-year locoregional control rate (response rate = 0.63; P = 0.005) compared with BRT.</s><s>BRT had a toxicity profile similar to CCRT and was difficult to deliver after TPF-ICT.</s><s>The aforementioned studies (TREMPLIN, PARADIGM and DeCIDE) suggested that, despite the fascinating nature of strategies using ICT and CCRT or BRT to control both locoregional and distant metastases, they have been difficult to implement because of their association with severe toxicities.</s></p><p><s>Thereafter, Mesia et al. (TTCC2007/02) reported feasible results for TPF-ICT (×3) → BRT in 93 patients with resectable laryngeal cancer (a Phase 2 study, with patients treated between 2008 and 2011) <ref type="bibr" target="#b55">[56]</ref>.</s><s>Among the 93 patients, 76 were responsive (37 CR + 38 PR = 81% response rate), while 73 patients (78%) received BRT.</s><s>The 3-year actuarial rates for survival with functional larynx, laryngectomy-free survival, and OS were 70%, 72% and 78%, respectively.</s><s>The acute toxicity observed during both ICT and BRT was expected, with only one toxicity-related death (local bleeding) during BRT.</s></p><p><s>Zenda et al. also postulated the feasibility of TPF-ICT × 3 → BRT in a Japanese population of 54 patients, 19% of which had laryngeal cancer (2013-2015) <ref type="bibr" target="#b56">[57]</ref>.</s><s>The response rates for ICT and RT were 72% and 76%, respectively.</s><s>Among the 54 patients, 50 (93%) received &gt;2 courses of ICT, whereas 41 (76%) had full-dose RT.</s><s>The rate of treatment completion was thus 76%.</s><s>The frequencies of Grade 3-4 neutropenia, febrile neutropenia, and allergic/infusion reactions were 93%, 39% and 11%, respectively.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>DISCUSSION</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>LP strategy may decrease OS</head><p><s>Despite treatment, the 5-year OS of locally advanced laryngeal cancer ranges from 30% to 70%.</s><s>Chen et al. <ref type="bibr" target="#b11">[12]</ref> reviewed 52 817 patients treated between 1985 and 2007 using the National Cancer Database, noting an increase in the administration of radiation with or without chemotherapy from &lt;7% to 45%.</s><s>Primary total laryngectomy decreased from 42% to 32%.</s><s>The 4-year OS rates for total laryngectomy, CCRT, and RT were 51%, 48% and 38%, respectively.</s><s>Using SEER data, Pulte et al. reported improvements in survival rates for head and neck cancer patients but not laryngeal cancer patients during the late 20th century <ref type="bibr" target="#b58">[58]</ref>.</s><s>This has also proven to be true for a recent series of cases diagnosed in the period 2004-2012, as reported by the National Cancer Database Analysis group in the USA <ref type="bibr" target="#b59">[59,</ref><ref type="bibr" target="#b60">60]</ref>.</s><s>A total of 1559 cases treated with S → RT, 1597 with CCRT, and 386 with ICT were included.</s><s>After adjusting for covariates, CCRT was found to be associated with inferior OS compared with S → RT (HR 1.55; P &lt; 0.01) and ICT (HR, 1.25 P &lt; 0.01).</s><s>These reports sparked controversy.</s><s>For example, inappropriate patient selection for the LP strategy may decrease survival of locally advanced laryngeal cancer.</s><s>Several important factors still need to be known before RCT outcomes can be translated into routine clinical work.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Limitations of RCTs</head><p><s>Locally advanced (Stage III/IV) tumors are considered to include cancers of Stages T2N1 to T4N3, which are evidently different categories.</s><s>The aforementioned RCTs sometimes included patients with T3 tumors without cord fixation and T4 tumors with minimal cartilage invasion.</s><s>For instance, the VA study showed that &lt;60% of the population had tumors with cord fixation, whereas all patients in the French GETTEC study presented with cord fixation, resulting in a superior OS after surgery.</s></p><p><s>In addition, T category migration is an important confounding factor.</s><s>Significant differences in the assessment of vocal cord fixation have been found between experts and trainees <ref type="bibr" target="#b61">[61]</ref>, which may lead to misclassifications of T2 and T3 categories.</s><s>Given that gross cartilage invasion was also difficult to detect using CT images <ref type="bibr" target="#b62">[62]</ref>, a substantial ratio of T4 tumors diagnosed using CT images may have actually been T3 tumors after pathological examination.</s><s>This is also true for magnetic resonance imaging (MRI) usage, which improved the diagnostic accuracy of T4 cartilage invasion.</s><s>Therefore, a discrepancy in T category classification exists between the previously used CT examinations and the more recently used MRI-based examinations.</s></p><p><s>Compliance with chemoradiotherapy (CRT) is another problem that needs to be addressed when interpreting RCTs.</s><s>The VA and GETTEC trials reported that only 7% and 0% of the patients discontinued CTX, respectively.</s><s>Moreover, the RTOG 9011 trial showed that 7% of the responders discontinued CTX after two cycles of ICT, whereas 70% of those receiving CCRT completed all three cycles of CTX.</s><s>On the other hand, Givens et al. showed that only 48% of the patients (including 16% with larynx) completed the planned CTX cycles <ref type="bibr" target="#b63">[63]</ref>.</s><s>A cumulative CDDP dosage of 200 mg or more indicated better outcomes when administered concurrently with RT <ref type="bibr" target="#b66">[66]</ref>.</s><s>Recent results suggest that larger amount of CDDP is associated with survival benefit in patients with human papillomavirus (HPV)-negative but not HPV-positive LAHNC, with the exception of the T4 or N3 subset wherein a higher cumulative cisplatin dose was associated with a trend toward improved OS <ref type="bibr" target="#b64">[64]</ref>.</s></p><p><s>Therefore, a huge bias exists between routine clinical practice and RCTs, such that most patients included in RCTs belong to a healthier population with less severe comorbidities, better functional status, and a lesser likelihood of suffering from adverse events related to treatments <ref type="bibr" target="#b65">[65]</ref>.</s></p><p><s>It is also important to emphasize that previous key trials were performed using two-dimensional RT techniques and that the use of more advanced RT techniques, such as IMRT and particle therapy, could probably lead to less late radiation toxicity.</s><s>Whether today's modern conformal radiation delivery systems reduce late normal tissue toxicity (other than that to the parotids) remains to be established <ref type="bibr" target="#b24">[25]</ref>.</s></p><p><s>Surgery remains as a best treatment for T4 disease for OS and requirement of multidiscipline team for LPF Sanabria et al. recommended that total laryngectomy be considered for advanced T4 laryngeal cancers in non-academic settings, given that its survival outcomes appear to be better than those for CCRT, according to the results of many observational studies <ref type="bibr" target="#b65">[65]</ref>.</s><s>CCRT can be acceptable for patients with T3 tumors given the condition that all resources for treatment follow-up, and surgical salvage are available.</s><s>Nakayama et al. noted that organ-sparing approaches require (i) a high level of skill and cooperation among various disciplines, (ii) adequate compliance from patients, and (iii) careful documentation and appropriate surveillance <ref type="bibr" target="#b66">[66]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>No strategy could add a merit in elder population</head><p><s>It should also be noted that all strategies to improve outcome, including CCRT, accelerated RT, and BRT, could not establish their merit with increasing age, showing no difference in survival vs conventional RT alone in patients older than 70 years of age <ref type="bibr" target="#b16">[17,</ref><ref type="bibr" target="#b42">43,</ref><ref type="bibr" target="#b50">51,</ref><ref type="bibr" target="#b67">67]</ref>.</s><s>Therefore, elderly patients should be given special consideration, carefully weighing the risks and benefits, before a treatment plan is decided upon.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>New paradigm shift</head><p><s>A new paradigm shift involving new drugs or technology is needed to improve not only OS but also LFP.</s><s>For example, HPV status could shed new light on the treatment algorithm of patients with oropharyngeal cancer <ref type="bibr" target="#b13">[14]</ref>.</s><s>Treatment intensity could potentially be reduced in patients positive for the virus.</s><s>Several candidates of molecular markers are also awaiting confirmation (p53, bclx, EGF, etc.) <ref type="bibr" target="#b68">[68]</ref>.</s></p><p><s>Several new drug combinations have also been explored.</s><s>Komatsu et al. explored experimental CCRT using TPF (×2) (docetaxel 50 mg/m 2 d1, CDDP 60 mg/m 2 d4, 5-FU 600 mg/m 2 d1-5) in 140 patients <ref type="bibr" target="#b69">[69]</ref>.</s><s>The response rate and 5-year OS rate were 97.1% and 79.2%, respectively.</s><s>Among patients with laryngeal or hypopharyngeal carcinoma, the 5-year laryngectomy-free survival rate was 64.9%.</s><s>Hoshikawa et al. reported on CCRT using Nedaplatin and S-1 <ref type="bibr" target="#b70">[70]</ref>.</s><s>Primary site tumors and neck lymph nodes exhibited CR rates of 91% and 64.3%, respectively, with a 4-year OS of 85.3%.</s><s>Several institutions have also explored intraarterial chemotherapy with good results.</s><s>Suzuki et al. reported 3-year OS and LP rates of 92% and 93%, respectively <ref type="bibr" target="#b71">[71]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>CONCLUSION</head><p><s>Regarding the first question, 'Is an LP strategy feasible?', the answer is 'yes' if the goal is set at improving the LP ratio.</s><s>However, appropriate eligibility criteria are still emerging and currently vary depending on the institution.</s></p><p><s>Regarding the second question 'Which treatment protocol is best?'</s><s>At present, this cannot be answered because the goal can vary (superior OS, better Quality of Life, less morbidity), depending on patient and physician preference.</s></p><p><s>In conclusion, options for LP, including CCRT, ICT, and BRT, have successfully emerged over the past several decades, without an improvement in OS.</s><s>A new paradigm shift involving new systemic therapies, molecular markers, and/or technology is needed to improve not only OS rates but also LFP.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>PY</head><label></label><figDesc><div><p><s>= year of publication, LC = local control rate (5 years unless otherwise stated), LP = larynx preservation (rate), LRC = locoregional control rate, FPR = functional preservation rate, OS = overall survival rate, DFS = disease-free survival rate, LFS = laryngectomy-free survival, MST = median survival time, NA = not available, RT = radiotherapy, ICT = induction chemotherapy, PF = CDDP + 5FU, FHX = 5-FU + hydroxyuria, CCRT = concurrent chemoradiotherapy, S = surgery, AF = alternated fractionation, Ch H = Christie Hospital Holt Radium Institute, UF = University of Florida, MDACC = MD Anderson Cancer Center, PMH = Princess Margaret Hospital.</s><s>a (1.5 Gy × 2 or 2 Gy/day × 5 days → 9-day interval) × 5-7 times.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head></head><label></label><figDesc><div><p><s>= treatment, PY = year of publication, MF = median follow-up period, ICT = induction chemotherapy, LP = larynx preservation (rate) (5 years unless otherwise stated), OS = overall survival, RT = radiotherapy, S = surgery, CCRT = concurrent chemoradiotherapy, PF = CDDP + 5FU, NA = not available, VA = Department of Veterans Affairs Laryngeal Cancer Study Group, GETTEC = Groupe d'Etude des Tumeurs de la TeÃ te et du Cou, RTOG = Radiation Therapy Oncology Group, LS = laryngectomy-free survival, FL = functioning larynx, CR = complete response, PR = partial response, RR = response rate = CR + PR. a Excluding T4 with thyroid cartilage or &gt;1 cm BOT invasion.</s><s>b Received more than 95% of the intended dose of radiotherapy (i.e. at least 67 Gy).</s><s>c Probably 100%, but not exactly stated.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Tx</head><label></label><figDesc><div><p><s>= treatment, PY = year of publication, MF = median follow-up period, RT = radiotherapy, CCRT = concurrent chemoradiotherapy, ICT = induction chmotherapy, LP = larynx preservation rate, OS = overall survival time (5 years unless otherwise stated), PFS = progression-free survival rate, PF = CDDP + 5FU, TPF = Taxan + CDDP + 5-FU, GORTEC = Groupe d'Oncologie Radiothérapie Tête Et Cou, EORTC = European Organization for Research and Treatment of Cancer, TTCC = Spanish Head and Neck Cancer Cooperative Group, DECIDE = Docetaxel-Based Chemotherapy Plus or Minus IC to Decrease Events in Head and Neck Cancer, CR = complete response, PR = partial response, RR = response rate = CR + PR, NA = not available, TTF = time to treatment failure.</s><s>a Estimated from graph.</s><s>b RT 72 Gy/1.8 + 1.5 Gy bid/6 wk + docetaxel 20 mg/m 2 /wk × 4 for poor responder at TPF-ICT or RT 70 Gy/35 fr + carboplatin AUC 1•5/week × 7 weeks for good responder.</s><s>c Low surgical curability or LP candidate.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Tx</head><label></label><figDesc><div><p><s>= treatment, PY = year of publication, MF = median follow-up period, RT = radiotherapy, ICT = induction chemotherapy, BRT = bioradiotherapy, BCCRT = biochemoradiotherapy, CCRT = concurrent chemoradiotherapy, LP = larynx preservation (rate), OS = overall survival rate (5 years unless otherwise stated), LC = local control rate, LRC = locoregional control rate, LRF = locoregional failure rate, PFS = progression-free survival rate, LFP = larynx function preservation, SFL = survival with functioning larynx, NS = not stated.</s><s>TREMPLIN = Radiotherapy With Cisplatin Vs Radiotherapy With Cetuximab After Induction Chemotherapy for Larynx Preservation, RTOG = Radiation Therapy Oncology Group.</s><s>a 70 Gy/35 fr or 72-76.8</s><s>Gy (1.2 Gy twice a day) concomitant boost 72 Gy.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 1 .</head><label>1</label><figDesc><div><p><s>Retrospective outcome of radiotherapy for T3-4 laryngeal cancer</s></p></div></figDesc><table><row><cell>T</cell><cell>Author (institution)</cell><cell>PY</cell><cell cols="2">NO PT Treatment</cell><cell>¶LC</cell><cell>¶LP</cell><cell>¶OS</cell></row><row><cell>category</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>T3</cell><cell>Wylie (ChH) [21]</cell><cell cols="2">1999 114</cell><cell>RT only: 50-55 Gy/</cell><cell>68%</cell><cell>NA</cell><cell>54%</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>3.3-3.4 Gy/fr (AF)</cell><cell></cell><cell></cell></row><row><cell></cell><cell>Hinerman (UF) [22]</cell><cell cols="2">2007 87</cell><cell>RT only: 50-79.2 Gy/</cell><cell>67%</cell><cell>NA</cell><cell>Stage III 52%</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>1.2-2 Gy/fr (AF)</cell><cell></cell><cell></cell></row><row><cell></cell><cell cols="3">Wolden (Michigan U) [23] 2009 73</cell><cell>FP → CCRT (or S)</cell><cell>3-year DFS 88%</cell><cell cols="2">3-year LFS 62% 3-year 83%</cell></row><row><cell></cell><cell>Al-Mamagami</cell><cell cols="2">2012 170</cell><cell>CCRT [70 Gy/35 6 fr/</cell><cell>68%</cell><cell>74%</cell><cell>60%</cell></row><row><cell></cell><cell>(Netherlands) [24]</cell><cell></cell><cell></cell><cell>week + CDDP]</cell><cell></cell><cell></cell></row><row><cell></cell><cell>Fuller (MDACC) [25]</cell><cell cols="2">2016 166</cell><cell>CCRT or ICT → RT</cell><cell cols="2">10-year LRC 76% 10-year 37%</cell><cell>67%</cell></row><row><cell></cell><cell></cell><cell></cell><cell>121</cell><cell>RT only</cell><cell></cell><cell>18%</cell><cell>50%</cell></row><row><cell></cell><cell></cell><cell></cell><cell>125</cell><cell>S → RT</cell><cell></cell><cell>NA</cell><cell>46%</cell></row><row><cell>T4</cell><cell>Harwood (PMC) [26]</cell><cell cols="2">1981 56</cell><cell>RT only: 50-55 Gy/</cell><cell>56%</cell><cell>NA</cell><cell>64.5%</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>2.2-2.5/fr (AF)</cell><cell></cell><cell></cell></row><row><cell></cell><cell>Hinerman (UF) [22]</cell><cell cols="2">2007 22</cell><cell>RT only: 50-79.2 Gy/</cell><cell>82%</cell><cell>NA</cell><cell>Stage IVa 67%</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>1.2-2 Gy/fr (AF)</cell><cell></cell><cell></cell></row><row><cell></cell><cell cols="3">Wolden (Michigan U) [23] 2009 36</cell><cell>FP→CCRT (or S)</cell><cell>3-year DFS 58%</cell><cell cols="2">3-year LFS 58% 3-year 78%</cell></row><row><cell></cell><cell cols="3">Stenson (Chicago U) [19] 2011 55</cell><cell>CCRT: RT 70-75 Gy</cell><cell>FPR 67.7%</cell><cell>88%</cell><cell>49%</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>(AF) a + FHX</cell><cell></cell><cell></cell></row><row><cell></cell><cell cols="3">Rosenthal (MDACC) [27] 2015 161</cell><cell>S → RT</cell><cell>78%</cell><cell>NA</cell><cell>MST 64 M</cell></row><row><cell></cell><cell></cell><cell></cell><cell>60</cell><cell>CCRT</cell><cell></cell><cell>33%</cell><cell>MST 64 M</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 2 .</head><label>2</label><figDesc><div><p><s>Randomized control trials for organ preservation in resectable cases</s></p></div></figDesc><table><row><cell>Study (Tx year)</cell><cell>Site stage</cell><cell>%T</cell><cell>NO</cell><cell cols="2">Tx (% RT received) % Tx</cell><cell>Initial response to</cell><cell>LP ¶</cell><cell>OS ¶</cell><cell>Toxicity</cell></row><row><cell></cell><cell></cell><cell>T1-2/</cell><cell>PT</cell><cell></cell><cell>complete</cell><cell>ICT (CCRT)</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>T3/T4</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Author PY</cell><cell>(MF)</cell><cell>%N</cell><cell></cell><cell>ICT (×3) unless</cell><cell></cell><cell>CR/RR</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>N0/N1/</cell><cell></cell><cell>otherwise stated</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>N2/N3</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="2">Control arm: surgery (S → RT)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>VA study</cell><cell cols="4">larynx III/IV 9/65/26 166 S → RT</cell><cell></cell><cell></cell><cell>NA</cell><cell>45%</cell><cell></cell><cell>same OS (PF lower</cell></row><row><cell>(1985-1988)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>meta, lower LC)</cell></row><row><cell>Wolf 1991 (USA)</cell><cell>(33 M)</cell><cell>54/18/</cell><cell cols="2">166 PF → RT (NA)</cell><cell>70%</cell><cell>RR 85%</cell><cell>3-year 64%,</cell><cell>42%</cell><cell>mucositis</cell><cell>LP feasible</cell></row><row><cell>[7]</cell><cell></cell><cell>11/17</cell><cell></cell><cell>(or S)</cell><cell></cell><cell></cell><cell>FL 39%</cell><cell></cell><cell>G2 ≤ 38%</cell></row><row><cell>GETTEC</cell><cell cols="2">larynx II-IV all T3</cell><cell cols="2">30 S → RT</cell><cell></cell><cell></cell><cell>NA</cell><cell>2-year 84%</cell><cell></cell><cell>S OS better</cell></row><row><cell>(1986-1989)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Richard 1998</cell><cell>(8.3Y)</cell><cell>78/15/</cell><cell cols="2">33 PF → RT (36%)</cell><cell>31%</cell><cell>13 PT ≥ 80%</cell><cell>42%</cell><cell cols="2">69% (P = 0.006) G2 ≤ 33%</cell><cell>early closure: PT</cell></row><row><cell>(France) [28]</cell><cell></cell><cell>11/7</cell><cell></cell><cell>(or S)</cell><cell></cell><cell>reduction (39%)</cell><cell></cell><cell></cell><cell></cell><cell>refused S</cell></row><row><cell>Singapore study</cell><cell>bulky T4 or</cell><cell cols="3">18/26/56 60 S → RT</cell><cell></cell><cell></cell><cell>NA</cell><cell>3-year DFS 50%</cell><cell></cell><cell>same</cell></row><row><cell>(1996-2002)</cell><cell>IVA</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Soo 2005 [29]</cell><cell>larynx 32%</cell><cell>49/46/5</cell><cell cols="2">59 CCRT a</cell><cell>69%</cell><cell>69.6%/92.8%</cell><cell>45%</cell><cell>40%</cell><cell>mucositis</cell><cell>early closure: poor</cell></row><row><cell></cell><cell>(6Y)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>G3 ≤ 39%</cell><cell>accrual</cell></row><row><cell cols="2">Control arm: radiotherapy (RT)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>RTOG91-11</cell><cell>larynx III/</cell><cell cols="3">11/79/10 173 RT</cell><cell>94% b</cell><cell></cell><cell>5-year 66%,</cell><cell>5-year 54%,</cell><cell>high grade</cell><cell>CCRT LP best, OS</cell></row><row><cell>(1992-2000)</cell><cell>IV a</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>10-year 64%</cell><cell>10-year 32%</cell><cell>81%</cell><cell>same</cell></row><row><cell>Forastiere 2013</cell><cell>(10.8Y)</cell><cell>50/21/</cell><cell cols="2">172 CCRT c</cell><cell>91% b</cell><cell></cell><cell>84%, 82%</cell><cell>55%, 28%</cell><cell>82%</cell><cell>CCRT acute worse,</cell></row><row><cell>(USA)[8, 30]</cell><cell>endpoint</cell><cell>28/2</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>(P &lt; 0.001)</cell><cell></cell><cell></cell><cell>late same</cell></row><row><cell></cell><cell>LP</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell cols="2">173 PF → RT (83%)</cell><cell>84% b</cell><cell>21%/83%</cell><cell>71%, 68%</cell><cell>59%, 39%</cell><cell>61%</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>(or S)</cell><cell></cell><cell></cell><cell>(P = 0.005)</cell><cell></cell><cell></cell></row><row><cell>Cleveland study</cell><cell>III/IV larynx</cell><cell cols="3">28/39/33 50 RT</cell><cell>NA c</cell><cell>CR 66%</cell><cell cols="2">LP 45%, LS 34% 48%</cell><cell>feeding tube</cell><cell>CCRT LP better,</cell></row><row><cell>(1990-1995)</cell><cell>18%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>32%</cell><cell>OS same, toxicity</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>worse</cell></row><row><cell>Adelstein 2000</cell><cell>(5 Y)</cell><cell>47/47/6</cell><cell cols="2">50 CCRT (FP)</cell><cell>NA c</cell><cell>94% (P &lt; 0.001)</cell><cell>77% (P &lt;</cell><cell></cell><cell></cell></row><row><cell>(USA [31]</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>0.001), 42%</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>(P = 0.</cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head></head><label></label><figDesc><div><p><s>The Cleveland studyAdelstein et al. confirmed the superiority of CCRT (5-FU 1000 mg/m 2 /day and CDDP 20 mg/m 2 /day, on Day 1 and Day 22, +RT 66-72 Gy/1.8-2</s><s>Gy/fr) over RT alone (66-72 Gy/1.8-2</s><s>Gy/fr) for LP but not OS in 100 patients with resectable American Joint Committee on Cancer Stage III and IV disease</s></p></div></figDesc><table /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_5"><head></head><label></label><figDesc><div><p><s>[37]Spanish Head and Neck Cancer Cooperative Group The Spanish Head and Neck Cancer Cooperative Group (TTCC) performed a comparison study between PF-ICT (CDDP 100 mg/m 2 Day 1 + 5-FU 1000 mg/m 2 Day 1-5 every 3 weeks) and TPF-ICT (paclitaxel 175 mg/m 2 Day 1, CDDP 100 mg/m 2 Day 2, 5-FU 500 mg/m 2 Days 2-6 every 3 weeks)[37].</s></p></div></figDesc><table><row><cell>Patients with a CR or</cell></row><row><cell>partial response (PR) of &gt;80% for the primary tumor received add-</cell></row><row><cell>itional CCRT. The PF and TPF arms had CR rates of 14% and</cell></row><row><cell>33% (P &lt; 0.001) and a median time to treatment failure (TTF) of</cell></row><row><cell>12 and 20 months (P = 0.006), respectively. TPF-ICT patients</cell></row><row><cell>tended to have longer OS (37 months in the PF-ICT arm vs 43</cell></row><row><cell>months in the TPF-ICT arm; P = 0.06). Moreover, this difference</cell></row><row><cell>was more evident in patients with unresectable disease (OS: 26</cell></row><row><cell>months in the PF-ICT arm vs 36 months in the TPF-ICT; P =</cell></row><row><cell>0.04). PF patients experienced more instances of Grade 2-4 muco-</cell></row><row><cell>sitis than TPF patients (53% vs 16%; P &lt; 0.001).</cell></row></table><note><p><s>Comparison with upfront CCRT (control arm: CCRT)Docetaxel-Based Chemotherapy Plus or Minus ICT to Decrease Events in Head and Neck Cancer (DeCIDE)Cohen et al.</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_6"><head>Table 3 .</head><label>3</label><figDesc><div><p><s>Randomized control trials of induction chemotherapy (ICT) including unresectable cases</s></p></div></figDesc><table><row><cell>Study (Tx year)</cell><cell>Stage</cell><cell>%T-T2/T3/</cell><cell>NO</cell><cell cols="2">RT (% received) Tx %</cell><cell>Initial response</cell><cell>LP</cell><cell>OS ¶</cell><cell>Toxicity</cell></row><row><cell></cell><cell></cell><cell>T4</cell><cell>PT</cell><cell></cell><cell>completed</cell><cell>ICT (CCRT)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Author PY</cell><cell>(MF)</cell><cell>%N N0/N1/</cell><cell></cell><cell>ICT (×3) if</cell><cell>[without</cell><cell>CR/RR (CR/</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>Endpoint</cell><cell>N2/N3</cell><cell></cell><cell>otherwise stated</cell><cell>delay or</cell><cell>RR)</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>reduced</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>dose]</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="3">ICT: PF vs TPF: control arm (PF-ICT → RT or CCRT)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Resectable</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>GORTEC2000-01</cell><cell>III/IV larynx</cell><cell>18/67/15</cell><cell cols="2">103 PF → RT (47%)</cell><cell cols="2">80% [32%] 30.1%/59.2%</cell><cell>3-year 57%</cell><cell>5y 50.9%, 10y</cell><cell>G3-late 17.1%</cell><cell>TPF better LP</cell></row><row><cell>(2000-2005)</cell><cell>46%</cell><cell></cell><cell></cell><cell>or CCRT</cell><cell></cell><cell></cell><cell></cell><cell>30.2%</cell><cell></cell><cell>same OS</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>(9%)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Pointeu 2009 [32,</cell><cell>(105 M) LP</cell><cell>39/23/33/4</cell><cell cols="2">110 TPF → RT</cell><cell>90%</cell><cell>41.8%/80%</cell><cell>70% (P = 0.03)</cell><cell>41.9%, 23.5%</cell><cell>9.3% (P = 0.035)</cell></row><row><cell>33]</cell><cell></cell><cell></cell><cell></cell><cell>(61%) or</cell><cell>[62.7%]</cell><cell>(P = 0.002)</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>CCRT (15%)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="2">Mix (resectable and unresectable)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>TAX 324</cell><cell>III/IV Larynx</cell><cell>25(T1-2)/</cell><cell cols="2">245 PF → CCRT</cell><cell>73%</cell><cell>15%/64%</cell><cell>3-year 32%, 3-</cell><cell>52%</cell><cell>feeding tube</cell><cell>TPF better LP OS</cell></row><row><cell>(1999-2003)</cell><cell>18%</cell><cell>32/43</cell><cell></cell><cell>(carboplatin)</cell><cell></cell><cell></cell><cell>year LFS 32%,</cell><cell></cell><cell>dependent 11%,</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>(75%)</cell><cell></cell><cell></cell><cell>3-year LRC</cell><cell></cell><cell>tracheostomies</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>70%</cell><cell></cell><cell>11%</cell></row><row><cell>Posner 2007 [34-</cell><cell>(72.2 M) OS</cell><cell cols="3">16/20/50/14 255 TPF → CCRT</cell><cell>68%</cell><cell>17%/72%(P =</cell><cell>52% (P = 0.02),</cell><cell>42%</cell><cell>3%, 7%</cell></row><row><cell>36]</cell><cell>PFS</cell><cell></cell><cell></cell><cell>(carboplatin)</cell><cell></cell><cell>0.07)</cell><cell>52%, 62%</cell><cell>(P = 0.014)</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>(79%)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="2">TTCC (1998-2001) III/IV larynx</cell><cell>11(T1-2)/</cell><cell cols="2">193 PF → CCRT</cell><cell>36%</cell><cell>14%/68%</cell><cell>NA</cell><cell>2-year 32%,</cell><cell>mucositis Grade 3</cell><cell>TPF better LP OS</cell></row><row><cell></cell><cell>16%</cell><cell>34/55</cell><cell></cell><cell>(42%)</cell><cell></cell><cell>(78%/88%)</cell><cell></cell><cell>MST 37M</cell><cell>≤53%</cell><cell>in unresectable</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>(unresectable</cell><cell></cell><cell>subpopulation</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>26 M)</cell><cell></cell></row><row><cell>Hitt 2005 (Spain)</cell><cell>(24 m) CR</cell><cell cols="3">21/19/47/13 189 T (paclitaxel)</cell><cell>60%</cell><cell>33% (P &lt;</cell><cell></cell><cell>43% 43M</cell><cell>16% (P &lt; 0.001)</cell></row><row><cell>[37]</cell><cell>rate</cell><cell></cell><cell></cell><cell>PF → CCRT</cell><cell></cell><cell>0.001)/80%</cell><cell></cell><cell>(P = 0.06),</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>(60%)</cell><cell></cell><cell>(88%/98%)</cell><cell></cell><cell>(36M</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>P = 0.03)</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell cols="2">128 CCRT (92%)</cell><cell>71%</cell><cell cols="2">(48.6%/90.5%) 13.8 M</cell><cell>27.6 M, 7.9 M</cell><cell>2 (1.5%)</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_7"><head>Table 4 .</head><label>4</label><figDesc><div><p><s>Randomized control trials for bioradiotherapy (BRT) including unresectable cases</s></p></div></figDesc><table><row><cell>Study (Tx year)</cell><cell>Stage</cell><cell>%T</cell><cell>NO</cell><cell>RT (% received)</cell><cell>Tx</cell><cell>LP</cell><cell>OS ¶</cell><cell>Toxicity</cell></row><row><cell></cell><cell>larynx %</cell><cell>T1-2/T3/T4</cell><cell>PT</cell><cell></cell><cell>% completed</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Author PY</cell><cell>(MF) Endpoint</cell><cell>%N</cell><cell></cell><cell>ICT (×3) unless</cell><cell>[without delay or</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>N0/N1/N2/N3</cell><cell></cell><cell>otherwise stated</cell><cell>reduced dose]</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Resectable</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>TREMPRIN</cell><cell cols="2">III/IV larynx 41% 14/56/30</cell><cell cols="2">60 TPF → CCRT (74%</cell><cell cols="2">90% CCRT allocated 3 M 95%,</cell><cell>18 M 92%</cell><cell>mucositis Grade 3</cell><cell>TPF→BRT same</cell></row><row><cell>(2006-2008)</cell><cell></cell><cell></cell><cell></cell><cell>TPF allocated)</cell><cell></cell><cell>LFP</cell><cell></cell><cell>≤46% (in-field</cell><cell>efficacy</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>87%</cell><cell></cell><cell>26%)</cell></row><row><cell>Lefebvre 2013</cell><cell>(36 M) 3 M LP</cell><cell>36/26/38/0</cell><cell cols="2">56 TPF → BRT (74%</cell><cell>95% BRT allocated</cell><cell cols="2">93%, 82% 89%</cell><cell>45% (57%)</cell><cell>BRT toxic as</cell></row><row><cell>[50]</cell><cell></cell><cell></cell><cell></cell><cell>TPF allocated)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>CCRT</cell></row><row><cell>Resectability NS</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Bonner trial</cell><cell cols="2">III/IV larynx 25% 31/39/30</cell><cell cols="2">213 RT a</cell><cell>unacceptable variation</cell><cell>3-year</cell><cell>36.4% MST</cell><cell>acneiform rush G3</cell><cell>BRT OS better in</cell></row><row><cell>(1999-2002)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>in RT 6%</cell><cell>LRC</cell><cell>49 M</cell><cell>≤0.5%</cell><cell>entire group</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>unevaluable RT</cell><cell>34%</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>6%</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Bonner 2006</cell><cell>(54 M) NA</cell><cell>19/19/53/9</cell><cell cols="2">211 BRT</cell><cell>4%, 9%</cell><cell>47%</cell><cell>45.6% (P =</cell><cell>8% (P &lt; 0.001)</cell><cell>BRT not superior</cell></row><row><cell>[14, 51]</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>0.03) 54 M</cell><cell></cell><cell>to RT in larynx</cell></row><row><cell>RTOG 0522</cell><cell cols="2">III/IV larynx 23% 39/37/24</cell><cell cols="2">447 CCRT</cell><cell>radiation</cell><cell cols="2">LRF 19.9% 3-year 72.9%,</cell><cell>mucositis Grade 3</cell><cell>same PFS, OS</cell></row><row><cell>(2005-2009)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>interruptions 42%</cell><cell></cell><cell>PFS 61.2%</cell><cell>≤33.3%</cell></row><row><cell>Ang 2014 [52]</cell><cell>(3.8-year) PFS</cell><cell>11/9/75/5</cell><cell cols="2">444 BCCRT</cell><cell>51% (P &lt; 0.001)</cell><cell>25.9%</cell><cell cols="2">75.8%, 58.9% 43.2%</cell><cell>P16 important</cell></row><row><cell>Italy PII</cell><cell cols="2">III/IV larynx 26% 24/33/43</cell><cell cols="2">35 CCRT cis40</cell><cell>100%</cell><cell>2-year LC</cell><cell>2-year 78%</cell><cell>severe 3%, RT stop 10</cell><cell>early closure: poor</cell></row><row><cell>(2011-2014)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>53%</cell><cell></cell><cell>days &lt;0%</cell><cell>accrual</cell></row><row><cell>Magrini 2016</cell><cell>(19.3 M) Tx</cell><cell>36/44/20</cell><cell cols="2">35 BRT</cell><cell>91%</cell><cell>80% P =</cell><cell>68%</cell><cell>19% (P = 0.044), 13%</cell><cell>BRT toxic than</cell></row><row><cell>[53]</cell><cell>compliance</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>0.07</cell><cell></cell><cell>(P = 0.05)</cell><cell>expected</cell></row></table></figure>
		</body>
		<back>
			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>CONFLICT OF INTEREST</head><p><s>The authors declare that they have no competing interests.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>FUNDING</head><p><s>The authors have no funding source.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Global cancer statistics</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Parkin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Bray</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Ferlay</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">CA Cancer J Clin</title>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="page" from="74" to="108" />
			<date type="published" when="2002">2002. 2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<monogr>
		<title level="m" type="main">What Patients Should Know in Decision Making</title>
		<author>
			<persName><forename type="first">Michigan</forename><surname>Medicine</surname></persName>
		</author>
		<ptr target="http://www.mcancer.org/head-and-neck-cancer/voicebox/what-patients-should-know" />
		<imprint>
			<date type="published" when="2017-04-10">10 April 2017</date>
		</imprint>
	</monogr>
	<note>Comprehensive Cancer Centre. date last accessed</note>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Clinical trial of CDDP and 5-FU infusion as initial treatment for advanced squamous cell carcinoma of the head and neck</title>
		<author>
			<persName><forename type="first">J</forename><surname>Kish</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Drelichman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Jacobs</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Treat Rep</title>
		<imprint>
			<biblScope unit="volume">66</biblScope>
			<biblScope unit="page" from="471" to="474" />
			<date type="published" when="1982">1982</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Adjuvant chemotherapy with cis-diamminodichloroplatinum II and 120-hour infusion 5-fluorouracil in Stage III and IV squamous cell carcinoma of the head and neck</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Decker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Drelichman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Jacobs</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer</title>
		<imprint>
			<biblScope unit="volume">51</biblScope>
			<biblScope unit="page" from="1353" to="1355" />
			<date type="published" when="1983">1983</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Chemotherapy as a substitute for surgery in the treatment advanced resectable head and neck cancer: a report from the Northern California Oncology Group</title>
		<author>
			<persName><forename type="first">C</forename><surname>Jacobs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Goffinet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Goffinet</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer</title>
		<imprint>
			<biblScope unit="volume">60</biblScope>
			<biblScope unit="page" from="1178" to="1183" />
			<date type="published" when="1987">1987</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Larynx preservation using induction chemotherapy plus radiation therapy as an alternative to laryngectomy in advanced head and neck cancer: a long-term follow-up report</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">D</forename><surname>Karp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">W</forename><surname>Vaughan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Carter</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="273" to="279" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">T</forename><surname>Wolf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">G</forename><surname>Fisher</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">324</biblScope>
			<biblScope unit="page" from="1685" to="1690" />
			<date type="published" when="1991">1991</date>
		</imprint>
		<respStmt>
			<orgName>Department of Veterans Affairs Laryngeal Cancer Study Group</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Forastiere</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Goepfert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Maor</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">349</biblScope>
			<biblScope unit="page" from="2091" to="2098" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group</title>
		<author>
			<persName><forename type="first">P</forename><surname>Blanchard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bourhis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Lacas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="2854" to="2860" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Chemotherapy in locally advanced head and neck squamous cell carcinoma</title>
		<author>
			<persName><forename type="first">B</forename><surname>Gyawali</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Shimokata</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Honda</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Treat Rev</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="page" from="10" to="16" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">The effect of induction chemotherapy using docetaxel, cisplatin, and fluorouracil on survival in locally advanced and neck squamous cell carcinoma: metaanalysis</title>
		<author>
			<persName><forename type="first">R</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hahn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Shin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Res Treat</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page" from="907" to="916" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Temporal trends in the treatment of early-and advanced-stage laryngeal cancer in the United States</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">Y</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Fedewa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Zhu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Otolaryngol Head Neck Surg</title>
		<imprint>
			<biblScope unit="volume">137</biblScope>
			<biblScope unit="page" from="1017" to="1024" />
			<date type="published" when="1985">1985-2007. 2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Laryngeal cancer in the United States: changes in demographics, patterns of care, and survival</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">T</forename><surname>Hoffman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Porter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">H</forename><surname>Karnell</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Laryngoscope</title>
		<imprint>
			<biblScope unit="volume">116</biblScope>
			<biblScope unit="page" from="1" to="13" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Bonner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename><surname>Harari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Giralt</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="21" to="28" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Radiotherapy for laryngeal cancer-technical aspects and alternate fractionation</title>
		<author>
			<persName><forename type="first">H</forename><surname>Yamazaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Suzuki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Nakamura</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Radiat Res</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="page" from="495" to="508" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Definitive radiotherapy for squamous cell carcinoma of the glottic larynx</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">M</forename><surname>Mendenhall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Dagan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Bryant</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Control</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="208" to="212" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Quantitative pretreatment CT volumetry: association with oncologic outcomes in patients with T4a squamous carcinoma of the larynx</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Shiao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Asr</forename><surname>Mohamed</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Messer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Head Neck</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="page" from="1609" to="1620" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">High-dose RT alone for patients with T4-stage laryngeal cancer</title>
		<author>
			<persName><forename type="first">A</forename><surname>Mucha-Małecka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Składowski</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Strahlenther Onkol</title>
		<imprint>
			<biblScope unit="volume">189</biblScope>
			<biblScope unit="page" from="632" to="638" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Chemoradiation for patients with large-volume laryngeal cancers</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Stenson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Maccracken</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">W</forename><surname>Kunnavakkam</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Head Neck</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="1162" to="1167" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Prognostic significance of thyroid or cricoid cartilage invasion in laryngeal or hypopharyngeal cancer treated with organ preserving strategies</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Wagner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">K</forename><surname>Curé</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Caudell</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Radiat Oncol</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page">219</biblScope>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Definitive RT for 114 cases of T3N0 glottic carcinoma: influence of dose-volume parameters on outcome</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Wylie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Swindell</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Radiother Oncol</title>
		<imprint>
			<biblScope unit="volume">53</biblScope>
			<biblScope unit="page" from="15" to="21" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">T3 and T4 true vocal cord squamous carcinomas treated with external beam irradiation: a single institution&apos;s 35-year experience</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">W</forename><surname>Hinerman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">M</forename><surname>Mendenhall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">G</forename><surname>Morris</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="181" to="185" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Chemoselection as a strategy for organ preservation in patients with T4 laryngeal squamous cell carcinoma with cartilage invasion</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">P</forename><surname>Worden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Moyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Lee</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Laryngoscope</title>
		<imprint>
			<biblScope unit="volume">119</biblScope>
			<biblScope unit="page" from="1510" to="1517" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">A single-institutional experience of 15 years of treating T3 laryngeal cancer with primary radiotherapy, with or without chemotherapy</title>
		<author>
			<persName><forename type="first">A</forename><surname>Al-Mamgani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Tans</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Van Rooij</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Radiat Oncol Biol Phys</title>
		<imprint>
			<biblScope unit="volume">83</biblScope>
			<biblScope unit="page" from="1000" to="1006" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Long-term outcomes after multidisciplinary management of T3 laryngeal squamous cell carcinomas: improved functional outcomes and survival with modern therapeutic approaches</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">D</forename><surname>Fuller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Mohamed</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Garden</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Head Neck</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="page" from="1739" to="1751" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">T4NOMO glottic cancer: an analysis of dose-time volume factors</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">A</forename><surname>Harwood Ar Beale</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">J</forename><surname>Cummings</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Radiat Oncol Biol Phys</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="1507" to="1512" />
			<date type="published" when="1981">1981</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Long-term outcomes after surgical or nonsurgical initial therapy for patients with T4 squamous cell carcinoma of the larynx: A 3-decade survey</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">I</forename><surname>Rosenthal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Mohamed</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Weber</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer</title>
		<imprint>
			<biblScope unit="volume">121</biblScope>
			<biblScope unit="page" from="1608" to="1619" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Randomized trial of induction chemotherapy in larynx carcinoma</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Richard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Sancho-Garnier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Pessey</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oral Oncol</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="224" to="228" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Surgery and adjuvant RT vs concurrent chemoradiotherapy in stage III/IV nonmetastatic squamous cell head and neck cancer: a randomised comparison</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">C</forename><surname>Soo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">H</forename><surname>Tan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Wee</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Cancer</title>
		<imprint>
			<biblScope unit="volume">93</biblScope>
			<biblScope unit="page" from="279" to="286" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Forastiere</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Weber</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="845" to="852" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Mature results of a phase III randomized trial comparing concurrent chemoradiotherapy with radiation therapy alone in patients with stage III and IV squamous cell carcinoma of the head and neck</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Adelstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Lavertu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Saxton</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer</title>
		<imprint>
			<biblScope unit="volume">88</biblScope>
			<biblScope unit="page" from="876" to="883" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Pointreau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Garaud</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Chapet</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Natl Cancer Inst</title>
		<imprint>
			<biblScope unit="volume">101</biblScope>
			<biblScope unit="page" from="498" to="506" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Long-term results of a multicenter randomized phase iii trial of induction chemotherapy with cisplatin, 5-fluorouracil, ± docetaxel for larynx preservation</title>
		<author>
			<persName><forename type="first">G</forename><surname>Janoray</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Pointreau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Garaud</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Natl Cancer Inst</title>
		<imprint>
			<biblScope unit="volume">108</biblScope>
			<biblScope unit="page">368</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Posner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Hershock</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>Blajman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">357</biblScope>
			<biblScope unit="page" from="1705" to="1715" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Lorch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Goloubeva</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">I</forename><surname>Haddad</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="153" to="159" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Posner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Norris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">J</forename><surname>Wirth</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Oncol</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="921" to="927" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer</title>
		<author>
			<persName><forename type="first">R</forename><surname>Hitt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Lopez-Pousa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Martinez-Trufero</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="8636" to="8645" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">E</forename><surname>Cohen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">G</forename><surname>Karrison</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kocherginsky</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="2735" to="2743" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Concomitant chemoradiotherapy versus induction docetaxel, cisplatin and 5 fluorouracil (TPF) followed by concomitant chemoradiotherapy in locally advanced head and neck cancer: a phase II randomized study</title>
		<author>
			<persName><forename type="first">A</forename><surname>Paccagnella</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Ghi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Loreggian</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Oncol</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="1515" to="1522" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Induction chemotherapy with docetaxel/CDDP/5-5-FU followed by randomization to two CDDP-based concomitant chemoradiotherapy schedules in patients (CONDOR study) (Dutch Head and Neck Society 08-01): a randomized phase II study</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Driessen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>De Boer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Gelderblom</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Cancer</title>
		<imprint>
			<biblScope unit="volume">52</biblScope>
			<biblScope unit="page" from="77" to="84" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer</title>
		<author>
			<persName><forename type="first">R</forename><surname>Hitt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Grau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Lopez-Pousa</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Oncol</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="216" to="225" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Phase II organpreservation trial: concurrent cisplatin and radiotherapy for advanced laryngeal cancer after response to docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy</title>
		<author>
			<persName><forename type="first">A</forename><surname>Popovtzer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Burnstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Stemmer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Head Neck</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="page" from="227" to="233" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Chemoselection: a paradigm for optimization of organ preservation in locally advanced larynx cancer</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Vainshtein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">F</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Spector</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Expert Rev Anticancer Ther</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="1053" to="1064" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Pignon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bourhis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Domenge</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">355</biblScope>
			<biblScope unit="page" from="949" to="955" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Pignon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Le Maitre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Maillard</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Radiother Oncol</title>
		<imprint>
			<biblScope unit="volume">92</biblScope>
			<biblScope unit="page" from="4" to="14" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Systematic review and meta-analysis of conventionally fractionated concurrent chemoradiotherapy versus altered fractionation radiotherapy alone in the definitive management of locoregionally advanced head and neck squamous cell carcinoma</title>
		<author>
			<persName><forename type="first">T</forename><surname>Gupta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kannan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ghosh-Laskar</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Oncol (R Coll Radiol</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="50" to="61" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">A systematic review of current and emerging approaches in the field of larynx preservation</title>
		<author>
			<persName><forename type="first">N</forename><surname>Denaro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">G</forename><surname>Russi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Lefebvre</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Radiother Oncol</title>
		<imprint>
			<biblScope unit="volume">110</biblScope>
			<biblScope unit="page" from="16" to="24" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Induction chemotherapy followed by concurrent radio-chemotherapy versus concurrent radio-chemotherapy alone as treatment of locally advanced squamous cell carcinoma of the head and neck (HNSCC): a meta-analysis of randomized trials</title>
		<author>
			<persName><forename type="first">W</forename><surname>Budach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Bölke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Kammers</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Radiother Oncol</title>
		<imprint>
			<biblScope unit="volume">118</biblScope>
			<biblScope unit="page" from="238" to="243" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">The current role of systemic chemotherapy in the primary treatment of head and neck cancer</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Busch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Tribius</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Schafhausen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Treat Rev</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="page" from="217" to="221" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II study</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Lefebvre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Pointreau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Rolland</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="853" to="859" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Bonner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename><surname>Harari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Giralt</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">354</biblScope>
			<biblScope unit="page" from="567" to="578" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">Randomized phase III trial of concurrent accelerated radiation plus CDDP with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">K</forename><surname>Ang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">I</forename><surname>Rosenthal</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="2940" to="2950" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main">Cetuximab and radiotherapy versus cisplatin and radiotherapy for locally advanced head and neck cancer: a randomized phase ii trial</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Magrini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Buglione</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Corvò</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="427" to="435" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main">Induction chemotherapy (IC) docetaxel (T), cisplatin (P), 5-fluorouracil (F) (TPF), or TP followed by concomitant boost radiotherapy (R) with or without cetuximab (E) for functional organ preservation (FOP) of resectable laryngeal and hypopharyngeal cancer (LHSCC): first results of the phase II randomized DeLOS-II study</title>
		<author>
			<persName><forename type="first">A</forename><surname>Dietz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Flentje</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Hagen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note>15_suppl):abstract 6016</note>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main">Concomitant platinumbased chemotherapy or cetuximab with radiotherapy for locally advanced head and neck cancer: a systematic review and metaanalysis of published studies</title>
		<author>
			<persName><forename type="first">F</forename><surname>Petrelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Coinu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Riboldi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oral Oncol</title>
		<imprint>
			<biblScope unit="volume">50</biblScope>
			<biblScope unit="page" from="1041" to="1048" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b55">
	<analytic>
		<title level="a" type="main">Could the addition of cetuximab to conventional radiation therapy improve organ preservation in those patients with locally advanced larynx cancer who respond to induction chemotherapy? An organ preservation Spanish Head and Neck Cancer Cooperative Group Phase 2 study</title>
		<author>
			<persName><forename type="first">R</forename><surname>Mesía</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Garcia-Saenz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Lozano</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Radiat Oncol Biol Phys</title>
		<imprint>
			<biblScope unit="volume">97</biblScope>
			<biblScope unit="page" from="473" to="480" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b56">
	<monogr>
		<title level="m" type="main">A multicenter phase II trial of docetaxel, cisplatin and cetuximab (TPE) followed by cetuximab concurrent with radiotherapy in patients with local advanced squamous cell carcinoma of the head and neck</title>
		<author>
			<persName><forename type="first">S</forename><surname>Zenda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Ota</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Kiyota</surname></persName>
		</author>
		<imprint/>
	</monogr>
	<note>ECRIPS study</note>
</biblStruct>

<biblStruct xml:id="b57">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page">6071</biblScope>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note>suppl</note>
</biblStruct>

<biblStruct xml:id="b58">
	<analytic>
		<title level="a" type="main">Changes in survival in head and neck cancers in the late 20th and early 21st century: a period analysis</title>
		<author>
			<persName><forename type="first">D</forename><surname>Pulte</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Brenner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncologist</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="994" to="1001" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b59">
	<analytic>
		<title level="a" type="main">T3-T4 laryngeal cancer in The Netherlands Cancer Institute; 10-year results of the consistent application of an organ-preserving/-sacrificing protocol</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Timmermans</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>De Gooijer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Hamming-Vrieze</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Head Neck</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="1495" to="1503" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b60">
	<analytic>
		<title level="a" type="main">A comparison of overall survival for patients with T4 larynx cancer treated with surgical versus organ-preservation approaches: a National Cancer Data Base analysis</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">A</forename><surname>Stokes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">L</forename><surname>Jones</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bhatia</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer</title>
		<imprint>
			<biblScope unit="volume">123</biblScope>
			<biblScope unit="page" from="600" to="608" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b61">
	<analytic>
		<title level="a" type="main">Laryngoscopy of vocal fold paralysis: evaluation of consistency of clinical findings</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Rosow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Sulica</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Laryngoscope</title>
		<imprint>
			<biblScope unit="volume">120</biblScope>
			<biblScope unit="page" from="1376" to="1382" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b62">
	<analytic>
		<title level="a" type="main">Prognostic accuracy of computed tomography findings for patients with laryngeal cancer undergoing laryngectomy</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Beitler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Muller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Grist</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="2318" to="2322" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b63">
	<analytic>
		<title level="a" type="main">Adverse events associated with concurrent chemoradiation therapy in patients with head and neck cancer</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Givens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">H</forename><surname>Karnell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">K</forename><surname>Gupta</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Otolaryngol Head Neck Surg</title>
		<imprint>
			<biblScope unit="volume">135</biblScope>
			<biblScope unit="page" from="1209" to="1217" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b64">
	<analytic>
		<title level="a" type="main">Impact of cisplatin dose intensity on human papillomavirus-related and -unrelated locally advanced head and neck squamous cell carcinoma</title>
		<author>
			<persName><forename type="first">A</forename><surname>Spreafico</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Xu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Cancer</title>
		<imprint>
			<biblScope unit="volume">67</biblScope>
			<biblScope unit="page" from="174" to="182" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b65">
	<analytic>
		<title level="a" type="main">Organ preservation with chemoradiation in advanced laryngeal cancer: the problem of generalizing results from randomized controlled trials</title>
		<author>
			<persName><forename type="first">A</forename><surname>Sanabria</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Chaves</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">P</forename><surname>Kowalski</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Auris Nasus Larynx</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="page" from="18" to="25" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b66">
	<analytic>
		<title level="a" type="main">Clinical outcomes of 849 laryngeal cancers treated in the past 40 years: are we succeeding?</title>
		<author>
			<persName><forename type="first">M</forename><surname>Nakayama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Okamoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Hayakawa</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Jpn J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="page" from="57" to="64" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b67">
	<analytic>
		<title level="a" type="main">Hyperfractionated or accelerated radiotherapy in head and neck cancer: a metaanalysis</title>
		<author>
			<persName><forename type="first">J</forename><surname>Bourhis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Overgaard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Audry</forename><forename type="middle">H</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">368</biblScope>
			<biblScope unit="page" from="843" to="854" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b68">
	<analytic>
		<title level="a" type="main">Effective biomarkers and radiation treatment in head and neck cancer</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Ow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Pitts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Kabarriti</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Pathol Lab Med</title>
		<imprint>
			<biblScope unit="volume">139</biblScope>
			<biblScope unit="page" from="1379" to="1388" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b69">
	<analytic>
		<title level="a" type="main">Concurrent chemoradiotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF) in patients with locally advanced squamous cell carcinoma of the head and neck</title>
		<author>
			<persName><forename type="first">M</forename><surname>Komatsu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Shiono</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Taguchi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Jpn J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="page" from="416" to="421" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b70">
	<analytic>
		<title level="a" type="main">Clinical outcomes of nedaplatin and S-1 treatment with concurrent RT in advanced head and neck cancer</title>
		<author>
			<persName><forename type="first">H</forename><surname>Hoshikawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Kishino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Mori</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Otolaryngol</title>
		<imprint>
			<biblScope unit="volume">135</biblScope>
			<biblScope unit="page" from="103" to="108" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b71">
	<analytic>
		<title level="a" type="main">Predisposing factors for larynx preservation strategies with non-surgical multimodality treatment for locally advanced (T3-4) larynx, hypopharynx and cervical esophageal disease</title>
		<author>
			<persName><forename type="first">G</forename><surname>Suzuki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Yamazaki</surname></persName>
		</author>
		<author>
			<persName><surname>Ogo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Anticancer Res</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="5205" to="5210" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
